Konrad Bochennek1, Regina Allwinn2, Rebecca Langer1, Martina Becker1, Oliver T Keppler2, Thomas Klingebiel1, Thomas Lehrnbecher3. 1. Pediatric Hematology and Oncology, Children's Hospital of the University of Frankfurt, Germany. 2. Institute of Medical Virology, University of Frankfurt, Germany. 3. Pediatric Hematology and Oncology, Children's Hospital of the University of Frankfurt, Germany. Electronic address: thomas.lehrnbecher@kgu.de.
Abstract
BACKGROUND: Intensive chemotherapy in children with cancer results in long-term impairment of humoral immunity. Whereas most studies to date focused on children with acute lymphoblastic leukemia (ALL), little data have been published on patients suffering from Hodgkin disease or from solid tumors. We therefore analyzed the loss of protective immunity (defined as immunity at the time of diagnosis and lack of immunity after completion of therapy) against vaccine-preventable diseases in children treated for various malignancies. METHODS: Children and adolescents <21 years of age at diagnosis and treated between 2001 and 2010 for various malignancies in the Department of Pediatric Hematology and Oncology, University of Frankfurt, were included in the retrospective chart review. Antibody levels against measles, mumps, rubella and varicella-zoster-virus (VZV) were routinely assessed at the time of diagnosis and within 12 months after completion of therapy. RESULTS: The study population consisted of 195 children (122 male); 80 patients had ALL, 15 acute myelogenous leukemia (AML), 18 non-Hodgkin lymphoma (NHL), 22 Hodgkin disease, and 60 various solid tumors. Overall, 27%, 47%, 19%, and 17% of the patients lost their humoral immunity against measles, mumps, rubella, and VZV, respectively. The risk of losing protective antibody titers depended on age with a higher risk in younger children. The loss of protective humoral immunity occurred significantly more often in patients with ALL compared to patients with any other underlying malignant disease (hematological malignancies such AML and NHL, Hodgkin disease or solid tumors). CONCLUSIONS: Our data demonstrate that a significant number of children lose pre-existing humoral immunity against measles, mumps, rubella, and VZV after completion of chemotherapy. This loss occurs more often in children with ALL than in children with AML, solid tumors and Hodgkin disease. Our results underline the need for post-chemotherapy revaccination of childhood cancer survivors.
BACKGROUND: Intensive chemotherapy in children with cancer results in long-term impairment of humoral immunity. Whereas most studies to date focused on children with acute lymphoblastic leukemia (ALL), little data have been published on patients suffering from Hodgkin disease or from solid tumors. We therefore analyzed the loss of protective immunity (defined as immunity at the time of diagnosis and lack of immunity after completion of therapy) against vaccine-preventable diseases in children treated for various malignancies. METHODS:Children and adolescents <21 years of age at diagnosis and treated between 2001 and 2010 for various malignancies in the Department of Pediatric Hematology and Oncology, University of Frankfurt, were included in the retrospective chart review. Antibody levels against measles, mumps, rubella and varicella-zoster-virus (VZV) were routinely assessed at the time of diagnosis and within 12 months after completion of therapy. RESULTS: The study population consisted of 195 children (122 male); 80 patients had ALL, 15 acute myelogenous leukemia (AML), 18 non-Hodgkin lymphoma (NHL), 22 Hodgkin disease, and 60 various solid tumors. Overall, 27%, 47%, 19%, and 17% of the patients lost their humoral immunity against measles, mumps, rubella, and VZV, respectively. The risk of losing protective antibody titers depended on age with a higher risk in younger children. The loss of protective humoral immunity occurred significantly more often in patients with ALL compared to patients with any other underlying malignant disease (hematological malignancies such AML and NHL, Hodgkin disease or solid tumors). CONCLUSIONS: Our data demonstrate that a significant number of children lose pre-existing humoral immunity against measles, mumps, rubella, and VZV after completion of chemotherapy. This loss occurs more often in children with ALL than in children with AML, solid tumors and Hodgkin disease. Our results underline the need for post-chemotherapy revaccination of childhood cancer survivors.
Authors: T N Figueira; L M Palermo; A S Veiga; D Huey; C A Alabi; N C Santos; J C Welsch; C Mathieu; B Horvat; S Niewiesk; A Moscona; M A R B Castanho; M Porotto Journal: J Virol Date: 2016-12-16 Impact factor: 5.103
Authors: Brent R Weil; Arin L Madenci; Qi Liu; Rebecca M Howell; Todd M Gibson; Yutaka Yasui; Joseph P Neglia; Wendy M Leisenring; Susan A Smith; Emily S Tonorezos; Danielle N Friedman; Louis S Constine; Christopher L Tinkle; Lisa R Diller; Gregory T Armstrong; Kevin C Oeffinger; Christopher B Weldon Journal: J Clin Oncol Date: 2018-04-17 Impact factor: 44.544
Authors: Bart N Ford; Robert H Yolken; Faith B Dickerson; T Kent Teague; Michael R Irwin; Martin P Paulus; Jonathan Savitz Journal: Psychol Med Date: 2018-03-19 Impact factor: 7.723
Authors: Andreas Engert; Carlo Balduini; Anneke Brand; Bertrand Coiffier; Catherine Cordonnier; Hartmut Döhner; Thom Duyvené de Wit; Sabine Eichinger; Willem Fibbe; Tony Green; Fleur de Haas; Achille Iolascon; Thierry Jaffredo; Francesco Rodeghiero; Gilles Salles; Jan Jacob Schuringa Journal: Haematologica Date: 2016-01-27 Impact factor: 9.941
Authors: Gregory M T Guilcher; Linda Rivard; Jennifer T Huang; Nicola A M Wright; Lynette Anderson; Hesham Eissa; Wendy Pelletier; Shanti Ramachandran; Tal Schechter; Ami J Shah; Ken Wong; Eric J Chow Journal: Lancet Child Adolesc Health Date: 2021-02-16